Cargando…

Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing

Empiric management in suspected heparin-induced thrombocytopenia (HIT) is challenging due to imperfect prediction models, latency while awaiting test results and risks of empiric therapies. When there is high clinical suspicion for HIT, cessation of heparin and empiric non-heparin anticoagulation wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dykes, Kaitlyn C., Johnson, Cassandra A., Gong, Jerald Z., McKenzie, Steven E., Husseinzadeh, Holleh D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047835/
https://www.ncbi.nlm.nih.gov/pubmed/33848189
http://dx.doi.org/10.1177/1076029621996473
_version_ 1783679120935223296
author Dykes, Kaitlyn C.
Johnson, Cassandra A.
Gong, Jerald Z.
McKenzie, Steven E.
Husseinzadeh, Holleh D.
author_facet Dykes, Kaitlyn C.
Johnson, Cassandra A.
Gong, Jerald Z.
McKenzie, Steven E.
Husseinzadeh, Holleh D.
author_sort Dykes, Kaitlyn C.
collection PubMed
description Empiric management in suspected heparin-induced thrombocytopenia (HIT) is challenging due to imperfect prediction models, latency while awaiting test results and risks of empiric therapies. When there is high clinical suspicion for HIT, cessation of heparin and empiric non-heparin anticoagulation with FDA-approved argatroban is recommended. Alternatively off-label fondaparinux or watchful waiting have been utilized in clinical practice. Outcomes of patients empirically managed for HIT have not been compared directly in clinical trials and patients that ultimately do not have HIT are often overlooked. Clinicians need studies investigating empiric management to guide decision making in suspected HIT. In this study, adverse events (AE) were categorized and compared in patients being evaluated for HIT while undergoing empiric management by non-heparin anticoagulation with argatroban or fondaparinux, both at therapeutic or reduced doses, or watchful waiting with or without heparin. AE were defined as new thrombosis confirmed on imaging or new bleeding event after HIT was first suspected. A retrospective chart review of 312 patients tested for HIT at an academic hospital was conducted. 170 patients met inclusion criteria. Patients were excluded if the 4Ts score was < 4. The 4Ts score is a pretest probability for HIT based on thrombocytopenia degree, timing, alternative causes and presence of thrombosis. Included patients were divided according to management groups and compared with logistic regression analysis. Bleeding risk significantly differed between management groups (p = 0.002). Despite adjustment for bleeding risk, fondaparinux was associated with increased AE, (p = 0.03, OR = 5.81), while argatroban was not. There was no difference in AE based on time to initiation of empiric treatment and no advantage to reduced dosing with either anticoagulant. These findings challenge assumptions surrounding empiric HIT management.
format Online
Article
Text
id pubmed-8047835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80478352021-04-27 Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing Dykes, Kaitlyn C. Johnson, Cassandra A. Gong, Jerald Z. McKenzie, Steven E. Husseinzadeh, Holleh D. Clin Appl Thromb Hemost Original Article Empiric management in suspected heparin-induced thrombocytopenia (HIT) is challenging due to imperfect prediction models, latency while awaiting test results and risks of empiric therapies. When there is high clinical suspicion for HIT, cessation of heparin and empiric non-heparin anticoagulation with FDA-approved argatroban is recommended. Alternatively off-label fondaparinux or watchful waiting have been utilized in clinical practice. Outcomes of patients empirically managed for HIT have not been compared directly in clinical trials and patients that ultimately do not have HIT are often overlooked. Clinicians need studies investigating empiric management to guide decision making in suspected HIT. In this study, adverse events (AE) were categorized and compared in patients being evaluated for HIT while undergoing empiric management by non-heparin anticoagulation with argatroban or fondaparinux, both at therapeutic or reduced doses, or watchful waiting with or without heparin. AE were defined as new thrombosis confirmed on imaging or new bleeding event after HIT was first suspected. A retrospective chart review of 312 patients tested for HIT at an academic hospital was conducted. 170 patients met inclusion criteria. Patients were excluded if the 4Ts score was < 4. The 4Ts score is a pretest probability for HIT based on thrombocytopenia degree, timing, alternative causes and presence of thrombosis. Included patients were divided according to management groups and compared with logistic regression analysis. Bleeding risk significantly differed between management groups (p = 0.002). Despite adjustment for bleeding risk, fondaparinux was associated with increased AE, (p = 0.03, OR = 5.81), while argatroban was not. There was no difference in AE based on time to initiation of empiric treatment and no advantage to reduced dosing with either anticoagulant. These findings challenge assumptions surrounding empiric HIT management. SAGE Publications 2021-04-13 /pmc/articles/PMC8047835/ /pubmed/33848189 http://dx.doi.org/10.1177/1076029621996473 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Dykes, Kaitlyn C.
Johnson, Cassandra A.
Gong, Jerald Z.
McKenzie, Steven E.
Husseinzadeh, Holleh D.
Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title_full Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title_fullStr Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title_full_unstemmed Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title_short Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
title_sort bleeding and thrombotic adverse events in hospitalized patients under empiric treatment for suspected heparin-induced thrombocytopenia while awaiting confirmatory testing
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047835/
https://www.ncbi.nlm.nih.gov/pubmed/33848189
http://dx.doi.org/10.1177/1076029621996473
work_keys_str_mv AT dykeskaitlync bleedingandthromboticadverseeventsinhospitalizedpatientsunderempirictreatmentforsuspectedheparininducedthrombocytopeniawhileawaitingconfirmatorytesting
AT johnsoncassandraa bleedingandthromboticadverseeventsinhospitalizedpatientsunderempirictreatmentforsuspectedheparininducedthrombocytopeniawhileawaitingconfirmatorytesting
AT gongjeraldz bleedingandthromboticadverseeventsinhospitalizedpatientsunderempirictreatmentforsuspectedheparininducedthrombocytopeniawhileawaitingconfirmatorytesting
AT mckenziestevene bleedingandthromboticadverseeventsinhospitalizedpatientsunderempirictreatmentforsuspectedheparininducedthrombocytopeniawhileawaitingconfirmatorytesting
AT husseinzadehhollehd bleedingandthromboticadverseeventsinhospitalizedpatientsunderempirictreatmentforsuspectedheparininducedthrombocytopeniawhileawaitingconfirmatorytesting